Wedbush Reiterates Their Buy Rating on United Therapeutics (UTHR)

By Jason Carr

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on United Therapeutics (UTHRResearch Report), with a price target of $273. The company’s shares opened today at $81.29, close to its 52-week low of $74.31.

According to, Moussatos has 0 stars on 0-5 star ranking scale with an average return of -11.6% and a 29.3% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Aquestive Therapeutics Inc, and Allena Pharmaceuticals Inc.

United Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $121.71, implying a 49.7% upside from current levels. In a report released today, Ladenburg Thalmann & Co. also upgraded the stock to Buy with a $106 price target.

See today’s analyst top recommended stocks >>

Based on United Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $205 million. In comparison, last year the company had a net profit of $173 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma.